IRADIMED Corporation Reports Strong Q1 2026 Results, Declares Cash Dividend, Reaffirms 2026 Outlook
Orlando, FL – May 1, 2026 – IRADIMED Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, has released its financial results for the first quarter of 2026, delivering robust growth in both revenues and earnings. The company also announced a regular quarterly cash dividend and reaffirmed its financial guidance for the full year 2026, signaling continued confidence in its business trajectory.
Key Financial Highlights
- Q1 2026 revenue: \$22.0 million, up 13% from \$19.5 million in Q1 2025
- Q1 2026 GAAP diluted EPS: \$0.45, a 22% increase from \$0.37 in Q1 2025
- Q1 2026 non-GAAP diluted EPS: \$0.49, a 17% increase from \$0.42 in Q1 2025
- Net income: \$5.8 million in Q1 2026, up 24% from \$4.7 million in Q1 2025
- Record free cash flow: \$7.8 million for Q1 2026
Shareholder Returns
- Dividend declared: The Board of Directors has declared a regular quarterly cash dividend of \$0.20 per share of common stock for Q2 2026.
- Dividend details: Payable to shareholders of record as of the close of business on May 15, 2026, with payment on May 29, 2026.
2026 Guidance Reaffirmed
- Q2 2026 Guidance:
- Revenue: \$20.0 million to \$21.0 million
- GAAP diluted EPS: \$0.40 to \$0.44
- Non-GAAP diluted EPS: \$0.44 to \$0.48
- Full-Year 2026 Guidance:
- Revenue: \$91.0 million to \$96.0 million
- GAAP diluted EPS: \$1.90 to \$2.05
- Non-GAAP diluted EPS: \$2.06 to \$2.21
- Stock-based compensation expense (net of tax): Expected at \$2.4 million for the year, and \$0.6 million for Q2 2026
Balance Sheet Strength
- Cash & equivalents: \$98.5 million in total stockholders’ equity as of March 31, 2026, up from \$94.6 million at the end of 2025
- Total assets: \$114.4 million as of March 31, 2026
- Total liabilities: \$15.9 million as of March 31, 2026
Operational Performance
- Operating income: \$7.2 million in Q1 2026, up from \$5.4 million in Q1 2025
- Other income: \$532,000 in Q1 2026
- Gross margin: Not explicitly stated, but implied to be strong based on net income growth
Price-Sensitive and Shareholder-Relevant Insights
- Record EPS and Free Cash Flow: The company achieved record EPS and free cash flow, underscoring efficient operations and strong demand for its products.
- Dividend Policy: The continuation of a regular quarterly dividend signals ongoing confidence in cash generation and shareholder returns.
- Reaffirmed Guidance: By reaffirming both quarterly and full-year guidance, IRADIMED signals to the market that it is on track with its growth strategy, which may support or drive share price appreciation.
- Balance Sheet Strength: With significant cash and low liabilities, the company maintains substantial financial flexibility for M&A, R&D, or further shareholder returns.
- Upcoming Catalysts: The company referenced expectations for commercialization and ramping revenue from its next-generation 3870 MRI-compatible IV infusion pump, which could be a future growth driver.
Forward-Looking Statements and Risks
The company reminds investors that its statements regarding financial guidance, future dividends, operational plans, and product launches are forward-looking and subject to risks, including potential changes in demand, operational disruptions, competition, regulatory changes, and broader macroeconomic or geopolitical factors.
Conference Call Details
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Financial results and forward-looking statements are subject to change and involve risks. Investors should review the company’s filings with the SEC and consult with financial advisors before making investment decisions.
View IRADIMED CORP Historical chart here
